165 related articles for article (PubMed ID: 36935674)
1. Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria.
Karanyotova S; Topova B; Petrova E; Doychev P; Kapitanska E; Petrova G; Mitkova Z; Dimitrova M
Front Public Health; 2023; 11():1073733. PubMed ID: 36935674
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patients' access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece.
Seitaridou Y; Tsekov I; Kamusheva M; Dimitrova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):241-246. PubMed ID: 34525887
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria - A Pilot Comparative Study.
Kamusheva M; Dimitrova M; Tachkov K; Petrova G; Mitkova Z
Front Pharmacol; 2021; 12():695181. PubMed ID: 34349654
[TBL] [Abstract][Full Text] [Related]
4. Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape.
Kostadinov K; Marinova Y; Dimitrov K; Hristova-Atanasova E; Iskrov G; Stefanov R
Healthcare (Basel); 2024 Feb; 12(4):. PubMed ID: 38391833
[TBL] [Abstract][Full Text] [Related]
5. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
6. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
Thill M
Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
[TBL] [Abstract][Full Text] [Related]
7. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
8. Access to medicines for rare diseases: A European regulatory roadmap for academia.
Rosenberg N; van den Berg S; Stolwijk NN; Jacobs BAW; Post HC; Pasmooij AMG; de Visser SJ; Hollak CEM
Front Pharmacol; 2023; 14():1142351. PubMed ID: 36925633
[No Abstract] [Full Text] [Related]
9. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.
Gherghescu I; Delgado-Charro MB
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396369
[TBL] [Abstract][Full Text] [Related]
10. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
11. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
12. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
13. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
[TBL] [Abstract][Full Text] [Related]
15. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
Aapro M; Krendyukov A; Schiestl M; Gascón P
BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
[TBL] [Abstract][Full Text] [Related]
16. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
Blackwell K; Gligorov J; Jacobs I; Twelves C
Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
[TBL] [Abstract][Full Text] [Related]
17. Availability and reimbursement of biological products for severe asthma in Bulgaria.
Milushewa P; Doneva M; Petrova G
SAGE Open Med; 2020; 8():2050312120951067. PubMed ID: 32922787
[TBL] [Abstract][Full Text] [Related]
18. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
19. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
20. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]